Clene (CLNN) director granted 1,893 stock options at $7.30
Clene Inc. (CLNN) disclosed a director stock option grant.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Clene Inc. (CLNN) disclosed a director stock option grant. On 11/13/2025, the director received an option for 1,893 shares of common stock at an exercise price of $7.30 per share under the Amended 2020 Stock Plan. The option vests immediately upon grant and expires on 11/12/2035.
Following the transaction, the filing shows 1,893 derivative securities beneficially owned, held in direct ownership.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | stock option | 1,893 | $0.00 | $0.00 |
Footnotes (1)
- F1. This option was granted on November 13, 2025 as an option for 1,893 shares of Common Stock under the Clene Inc. Amended 2020 Stock Plan at an exercise price of $7.30 per share. The options vest immediately upon grant.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Clene (CLNN) report in this Form 4?
When was the stock option granted for CLNN?
What is the vesting schedule of the CLNN option grant?
When does the CLNN option expire?
How many derivative securities are beneficially owned after the transaction?
Under which plan was the CLNN option granted?
What is the reported ownership form for the option?
AI-generated analysis. How Rhea-AI works. Not financial advice.